Stemtech Business Summary

Stemtech Corporation (OTC: STEK) is a nutraceutical pioneer specializing in "stemceuticals™," a category of plant-based supplements designed to support the body’s natural renewal system by enhancing adult stem cell release and circulation. The company operates a dual-track revenue model: a legacy global network marketing structure powered by Independent Business Partners (IBPs) and a newly launched "BioSciences" e-commerce retail channel (introduced February 2026) aimed at direct-to-consumer sales via digital platforms. Primary business segments include Stem Cell Nutrition (flagship RCM System), Skin Care (Cellect One), Oral Care (OraStem), and Pet Care (StemPets), with a significant portion of revenue historically derived from Latin American markets. Stemtech maintains a specialized market position as a category creator in cellular regeneration, competing directly with LifeVantage, Immunotec, and 4Life Research while aggressively expanding its footprint through 2026 joint ventures in China and India. The leadership team is anchored by Chairman and CEO Charles S. Arnold, a corporate strategist with over 35 years of experience in financial restructuring and direct sales, and President/COO John W. Meyer, who has overseen global operations since 2006 with a background at Shaklee and Arbonne. In early 2026, the company strengthened its executive suite by appointing Dr. Lizette Leos as Chief Scientific Officer to lead global scientific validation and regulatory alignment for international markets. Financial operations are directed by CFO Srilakshmi Vadlapatla, who manages the company’s global accounting and compliance functions. This leadership core is currently focused on a "Live Longer, Live Better" strategic pivot, transitioning the firm from a traditional MLM into a multi-channel wellness enterprise supported by a Life Sciences Advisory Board that includes prominent medical experts like Dr. Zahooruddin.